GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (FRA:9EN) » Definitions » Inventories, Raw Materials & Components

Pharvaris NV (FRA:9EN) Inventories, Raw Materials & Components : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Inventories, Raw Materials & Components?

Pharvaris NV's inventories, raw materials & components for the quarter that ended in Sep. 2024 was €0.00 Mil.


Pharvaris NV Inventories, Raw Materials & Components Historical Data

The historical data trend for Pharvaris NV's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV Inventories, Raw Materials & Components Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
Get a 7-Day Free Trial - - - - -

Pharvaris NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharvaris NV Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Pharvaris NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (FRA:9EN) » Definitions » Inventories, Raw Materials & Components
Traded in Other Exchanges
Address
Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Pharvaris NV Headlines

No Headlines